Dott.ssa Chiaravalloti Adele

Dr. Adele Chiaravalloti

Pubblications: PubMed

Operative Unit: Medical Retina Operating Unit

Sub-specialties: Age-related Macular Degeneration (AMD), macular edema, vitreoretinal diseases

Clinical activity: Dr. Adele Chiaravalloti since 2004 performs clinical activity at the IRCCS G.B. Bietti using OCT, fluorescence retinal angiography, indocyanine green angiography, microperimetry and treatment of chorioretinal and macular deseases by laser, photodynamic therapy, intravitreal injections of anti-VEGF drugs


Education

2003 Specialization in Ophthalmology at "La Sapienza" University of Rome
1999 Degree in Medicine and Surgery at "La Sapienza" University of Rome

Roles

Since 2008 consultant in the Maculopathy Center of the Fondazione G.B. Bietti – IRCCS in ASL Complesso Ospedaliero S.Giovanni-Addolorata, Rome
Since 2006 researcher in the Medical Retina Department of the Fondazione G.B. Bietti – IRCCS
2004/2005 Fellowship on "Retinal Surgery" at Fondazione G.B. Bietti

Co-Investigator in the multicentric studies

  • MONTBLANC Study. A 12-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with LucentisTM versus LucentisTM monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Co-Investigator.
  • View2 Study. A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular degeneration (AMD). Co-Investigator.
  • DEGAS Study. A phase II prospective, randomized, multi-center, diabetic macular edema dose ranging, comparator study evaluating the efficacy and safety of PF-04523655 versus laser therapy (DEGAS). Co-Investigator.
  • GALILEO Study. A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO). Co-Investigator.
  • MIZAR Study. A clinical safety and efficacy comparison of NEVANAC® 0.1% to Vehicle following cataract surgery in diabetic retinopathy patients. Co-Investigator.
  • A 12 month, phase III, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs verteporfin PDT in patients with visual impairment due to choroidal neovascularisation secondary to pathologic myopia. Study Coordinator.
  • RETAIN Study. A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs 0.5 mg ranibizumab as needed in patients with macular edema and visual impairment secondary to diabetes mellitus. Co-investigator.
  • COMO Study. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of Ozurdex® versus Lucentis® in patients with branch retinal vein occlusion. Co-Investigator.
  • VIVID DME Study. A randomised, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macula edema. Co-Investigator.
  • A Multicenter, Open-label, Randomized Study Comparing the       Efficacy and Safety of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema. Co-Investigator.
  • MINERVA Study. A 12-month, randomized, double-masked, sham-controlled,  multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV). Co-investigator.
  • TREND Study. A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5 mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration. Co-investigator.
  • FOVISTA Study. A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of FOVISTATM (anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration. Co-investigator.
  • TWEYES Study. A 12 months, prospective, multicenter, open-label, single arm interventional study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA below 2/10 and/or second affected eye. Study Coordinator.
  • A Multicenter, Open-label, Randomized Study Comparing the  Efficacy and Safety of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema.
  • A phase 3 randomized, double-masked, controlled trial to estblish the safety and efficacy of intravitreous administration of Fovista (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
  • A 12- month, randomized, double-masked, sham- controlled, multicenter study to evaluate the efficacy and safety of 0,5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial qrowth factor (VEGF) driven choroidal neovascularization (CNV).
  • An open label randomized,active-controlled, parallel-group, Phase-3b study of the efficacy, safety,and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular de generation (nAMD)AZURE
  • Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized,open-label, active-controlled, parallel-group phase IV/IIIb study (ARIES)
  • A multi-center, single arm,interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion CENTERA
  • Safety and efficacy of Abicipar Pegol in patients with neovascular Age-related Macular Degeneration.